To access this material please log in or register

Register Authorize

Actual Issues of Choosing Anticoagulant Therapy for Long-term Prophylaxis of Thromboembolic Complications

Pavlova T. V.1, Voronova I. L.1, Duplyakov D. V.1, 2
1Samara State Medical University, Samara, Russia
2Samara Regional Cardiology Dispensary, Samara, Russia

Keywords: atrial fibrillation; chronic heart failure; chronic kidney disease; anticoagulant therapy

DOI: 10.18087/cardio.2017.10021

The article contains presentation of actual problems of selection of anticoagulant therapy for long term prevention of thromboembolic complications in outpatients with atrial fibrillation, chronic heart failure, and chronic kidney disease.tions in ambulatory Patients with atrial fibrillation, chronic heart failure and chronic kidney disease.
  1. Chugh S.S., Havmoeller R ., Narayanan K. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129:837–847.
  2. Dzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991;121(4 Pt 1):1244–1263.
  3. Olesen J.B., Lip G.Y., Kamper A.L. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367(7):625–635.
  4. Benjamin E.J., Levy D., Vaziri S.M. et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271(11):840–844.
  5. Cleland J.G., Chattopadhyay S., Khand A. et al. Prevalence and incidence of arrhythmias and sudden death in heart failure. Heart Fail Rev 2002;7(3):229–242.
  6. Bos M.J., Koudstaal P.J., Hofman A., Breteler M.M. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam Study. Stroke 2007;38:3127–3132.
  7. Sarnak M.J., Levey A.S., Schoolwerth A.C. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003;42:1050–1065.
  8. Watanabe H., Watanabe T., Sasaki S. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J 2009;158(4):629–636.
  9. Zimmerman D., Sood M.M., Rigatto C. et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 2012;27:3816–3822.
  10. Ronco C., McCullough P., Anker S. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J 2010;31:703–711.
  11. Iguchi Y., Kimura K., Kobayashi K. Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol 2008;102(8):1056–1059.
  12. Go A.S., Fang M.C., Udaltsova N. et al.; ATRIA Study Investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009;119:1363–1369.
  13. Olesen J.B., Lip G.Y., Kamper A.L. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367(7):625–635.
  14. ESC Guidelines. Management of atrial fibrillation. Eur Heart J 2016;37(38):2893–2962.
  15. Tereshchenko S. N., Romanova N. V., Zhirov I. V. et al. The Russian registry of patients with chronic heart failure and atrial fibrillation (RIF-CHF): the clinical and demographic characteristics of the sample at the time of inclusion in the register. Journal of Heart Failure 2016; 17 (6): 418–426. Russian (Терещенко С. Н., Романова Н. В., Жиров И. В. и др. Российский регистр больных хронической сердечной недостаточностью и фибрилляцией предсердий (РИФ-ХСН): клинико-демографические характеристики выборки на момент включения в регистр. Журнал Сердечная недостаточность 2016;17 (6):418–426).
  16. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857–867.
  17. Cherian T.S., Shrader P., Fonarow G.C. et al. Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]). Am J Cardiol 2017;119(11):1763–1769.
  18. Beyer-Westendorf J., Forster K., Pannach S. et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: Results from the Dresden NOAC registry. Blood 2014;124(6):955–962.
  19. Michalski F., Tittl L., Werth S. et al. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry. Thromb Haemost 2015;114(5):1076–1084.
  20. Coleman C.I., Roberts M.S., Sobieraj D.M. et al. Curr Med Res Opin 2012;28(5):669–680.
  21. van Diepen S., Hellkamp A.S., Patel M.R. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail 2013;6(4):740–747.
  22. Fox K.A., Piccini J.P., Wojdyla D. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32(19):2387–2394.
  23. Fordyce C.B., Hellkamp A.S., Lokhnygina Y. et al. On-Treatment Outcomes in Patie3 4nts With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. Circulation 2016;134(1):37–47.
  24. Hijazi Z., Hohnloser S.H., Andersson U. et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time. Insights From the ARISTOTLE Randomized Clinical Trial JAMA Cardiol 2016;1(4):451–460.
  25. McHorney C.A. et al., Rivaroxaban users have significantly less treatment discontinuation compared with users of other oral anticoagulants in non-valvular atrial fibrillation. American College of Cardiology Conference 2017, Washington, DC, USA, 17–19 March 2017; Poster 1252–1306.
  26. Andrade J.G., Krahn A.D., Skanes A.C. et al. Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention. Can J Cardiol 2016;32(6):747–753.
  27. Beyer-Westendorf J., Forster K., Ebertz F. et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace 2015;17(4):530–538.
  28. McHorney C.A., Peterson E.D., Lalibertе F. et al. Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation. Clin Ther 2016;38(11):2477–2488.
Pavlova T. V., Voronova I. L., Duplyakov D. V. Actual Issues of Choosing Anticoagulant Therapy for Long-term Prophylaxis of Thromboembolic Complications. Kardiologiia. 2017;58(8):71–79.

To access this material please log in or register

Register Authorize
Ru En